Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis.

Dermatol Ther (Heidelb) · 2022 · PMC8941028 · PMID 35195887

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Notably, while there were small numerical differences in cumulative benefit between ixekizumab and risankizumab for both complete and almost-complete skin clearance, these did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.